Dupilumab, a monoclonal antibody targeting interleukin 4 and interleukin 13 receptors, is US Food and Drug Administration-approved for the treatment of a range of atopic conditions including atopic dermatitis, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyposis, as well as for treatment of prurigo nodularis. Here, IL4 is linked to atopic eczema.